Clinical utility of the anti-CCP assay in patients with rheumatic diseases. - Wikidata - awgldk - TriplyDB

Clinical utility of the anti-CCP assay in patients with rheumatic diseases.

Clinical utility of the anti-CCP assay in patients with rheumatic diseases.

http://www.wikidata.org/entity/Q35553110

about

Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review The use and abuse of diagnostic/classification criteria Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody for juvenile idiopathic arthritis Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis--cross-sectional study and literature review The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients.Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis.Efficacy of three ELISA measurements of anti-cyclic citrullinated peptide antibodies in the early diagnosis of rheumatoid arthritis.Anti-cyclic citrullinated peptide antibodies and paraoxonase-1 polymorphism in rheumatoid arthritis.Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis.Electronic medical records for discovery research in rheumatoid arthritis.Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis CYB5A polymorphism increases androgens and reduces risk of rheumatoid arthritis in women.Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis.A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells.Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project).Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis Autoantibodies to citrullinated (poly)peptides: a key diagnostic and prognostic marker for rheumatoid arthritis.Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destruction.Autoantibodies to citrullinated proteins: ACPA.Identification of rheumatoid arthritis patients using an administrative database: a Veterans Affairs study.Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis.On silico peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions.Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis.The association of anti-CCP1 antibodies with disease activity score 28 (DAS-28) in rheumatoid arthritis Associations of autoantibodies, autoimmune risk alleles, and clinical diagnoses from the electronic medical records in rheumatoid arthritis cases and non-rheumatoid arthritis controls.Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgaris Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis.The association of anti-CCP antibodies with disease activity in rheumatoid arthritis Anti-cyclic citrullinated peptide, rheumatoid factor, and ocular symptoms typical of rheumatoid arthritis.Anti-cyclic citrullinated peptide antibody is a good indicator for the diagnosis of rheumatoid arthritis The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases.Anti-cyclic citrullinated peptide and rheumatoid factor in patients with chronic hepatitis B and hepatitis B carriers.Anti-cyclic citrullinated peptide antibodies in children with Juvenile Idiopathic Arthritis.Autoimmunity to citrullinated type II collagen in rheumatoid arthritis

P2860

Q24675281-79469767-5C10-4598-B364-043E68A24D96 Q26865606-8078EE1B-BD1B-4DC0-A008-976B8219A5AA Q26991453-0ED5B587-BF24-4AC9-8A4A-30B9FD517B36 Q27001098-38371F93-BBFA-4879-934D-4BA2DF70C09D Q27022645-3A9861BF-5608-4A2E-8E81-B3ACF380B3A7 Q33893960-F7E50795-50AD-414C-BD65-CFC25FA1CE23 Q34244715-C1E2E1A6-655E-4F52-B4E2-046165ACCB0E Q34460622-85291FF9-B9D9-431D-95E3-0EE532DE0A58 Q34586496-F43451A5-58D5-44E8-ADA3-8FC6295A8DE0 Q35024495-8AABFCB9-CA60-4154-A36B-F305AA5E2D25 Q35062205-A4FC6639-EFC1-4346-931C-26E31EDAB767 Q35177819-55935081-7DFA-409A-8D85-CA200BFE8CE9 Q35207886-B1C0166A-3C24-4A60-A73B-50FAFA782E62 Q35212919-602F7898-8CD4-4571-9133-A663BEC56103 Q35475541-45160C18-6B26-4D21-BEF2-C053C7395CA8 Q35553508-1EACD141-F810-4BA4-A561-8773187A46C0 Q35554481-0DBA7BE4-5C7B-400C-AECB-98A67B69CC45 Q35554508-15CCE518-3C12-4104-95F5-D1246FBEE0FC Q35555882-2949C76C-DD6D-43E7-899E-781F78F19DEF Q35636615-B467327D-DE38-49D6-A4BB-3FD25E5249D1 Q35636880-9D6E293F-DBB8-4641-8565-CAEEF13EF22C Q35808002-CFC70C08-3BCE-4A8F-BDBE-E10AB011968C Q35934700-CA3BB75D-BD71-4D73-B347-5EA05A218244 Q35973747-D132AD61-29F2-40DE-BEE5-83EC71F616A6 Q36086129-04428E9F-F1CF-4AF8-B4B3-B40E9EDF899B Q36199089-4DB6BF8F-CEFA-4790-AFF4-7FBAC1397B8A Q36226393-9476D53B-769B-4EF4-9BB0-9A36A2CE53B0 Q36377207-3A424EDF-0FD3-4AB9-ACFF-B87BA44C8F50 Q36395509-49E83DE6-BC31-4F77-912F-FA8470D86EAB Q36425074-BCE2EA36-B187-4D84-B936-4BD2342B3F1D Q36639920-A9BBDD88-D15D-439D-A6BC-EC044D3BA5C5 Q36733774-F56BF55E-314F-417D-868D-24CC8A1DCC40 Q36740473-24905D8F-73E6-4A5B-8B54-54E359D6D8C3 Q36805269-E96ECA25-70FF-4C81-9561-2DC0D6A755C2 Q37106351-2F1C9EE6-EE1F-4E3A-A0CC-904993A3C8F0 Q37258094-0EAF1C67-E8FA-4335-93CD-2D518CEF77A6 Q37280952-3DE0BFA8-3C55-4378-9F09-B5DAAE1CB419 Q37305188-FCBD0CDA-3EAA-4D6F-9AE2-B70356CC0BD4 Q37358171-62A1D6C2-7F49-4CE1-B8EF-28B71CA34189 Q37428764-14098068-F1FF-40AD-8327-945086D57C98

P2860

Clinical utility of the anti-CCP assay in patients with rheumatic diseases.

http://www.wikidata.org/entity/Q35553110

description

2003 nî lūn-bûn

@nan

2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Clinical utility of the anti-CCP assay in patients with rheumatic diseases.

@ast

Clinical utility of the anti-CCP assay in patients with rheumatic diseases.

@en

type

label

Clinical utility of the anti-CCP assay in patients with rheumatic diseases.

@ast

Clinical utility of the anti-CCP assay in patients with rheumatic diseases.

@en

prefLabel

Clinical utility of the anti-CCP assay in patients with rheumatic diseases.

@ast

Clinical utility of the anti-CCP assay in patients with rheumatic diseases.

@en

P1433

Q35553110-3C9954B0-F54A-4D37-A5AA-F098B4538091

P1476

Q35553110-C18F39B6-EE2D-484C-87DB-2F25936AE3C9

P2093

Q35553110-9A753AF7-7DAF-4C02-A56E-56590B11D30C

Q35553110-A9DE7785-25F2-4E6A-9312-A22E4C013195

P2860

Q35553110-0BC3F95A-EC21-4E31-9343-272527FF504E

Q35553110-11E07264-EDEA-43FD-A4A4-5B9DDCFA93DC

Q35553110-20E7CA3A-E50B-4616-ABD3-BA45D8400398

Q35553110-45C627F7-D99D-4D4B-B32B-DF0553F81384

Q35553110-46F74BF6-E8C6-4926-A6C6-52E8E7883F4A

Q35553110-490EEE29-E4FA-4284-AB6A-42E0BDC6EA93

Q35553110-4C1EB44D-7AD2-4015-B764-6C69430D9232

Q35553110-77757164-2C42-4C11-BA2C-745957BAD2E1

Q35553110-7B34D8EB-B7B8-4A91-BCB6-0BE05FE5EB24

Q35553110-7C8A93B9-8010-4299-9C60-365B9A2C847D

P304

Q35553110-40F61823-0376-47A2-8BCA-42526E3CBE90

P31

Q35553110-1517646B-C8EC-42DF-9C00-87A19C43BF0A

P356

Q35553110-4974F9F7-E69C-40D5-B2DD-A6DB5D8C5830

P407

Q35553110-6BD0AD82-7DA1-4254-97A8-C8E80A905EAB

P433

Q35553110-B2A2AD7E-1E3A-4472-97CA-E8BE845F1313

P478

Q35553110-B141FE8E-0144-4FCA-9266-12564F2ECDA2

P577

Q35553110-7A7980F2-3EAF-4E4F-AFD0-7755780FF668

P5875

Q35553110-EB3314E7-E008-4D3E-874A-E6925B0B97D6

P698

Q35553110-E6F89866-11E4-4DFE-A948-8426C3920D83

P921

Q35553110-5E05A1BB-91F9-4FF8-8DBF-4F4C1F2FB78B

P932

Q35553110-C270F6D6-8A78-49C1-BBFA-E6A411F01DDD

P356

P1433

Annals of the Rheumatic Diseases

P1476

Clinical utility of the anti-CCP assay in patients with rheumatic diseases.

@en

P2093

Lee DM

http://www.w3.org/2001/XMLSchema#string

Schur PH

http://www.w3.org/2001/XMLSchema#string

P2860

Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies

Anti-keratin antibodies in rheumatoid arthritis

Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

DEMONSTRATION OF A NEW ANTINUCLEAR FOR RHEUMATOID ARTHRITIS ANTIBODY (ANTI-RA33) THAT IS HIGHLY SPECIFIC

The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis

A NEW SERUM FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS; THE ANTIPERINUCLEAR FACTOR.

Prognostic factors in early rheumatoid arthritis.

The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis.

The rheumatoid factor: an analysis of clinical utility.

P304

870-874

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.62.9.870

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P577

2003-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10610131

http://www.w3.org/2001/XMLSchema#string

P698

12922961

http://www.w3.org/2001/XMLSchema#string

P921

P932

1754666

http://www.w3.org/2001/XMLSchema#string